OBJECTIVES: All recombinant human growth hormones (rhGH) have the same molecular structure, therefore providing equal efficacy and safety, and are granted the same reimbursement in the Czech Republic (CR). All rhGH are currently administered subcutaneously once a day, differing only in applicators. Easypod is the only applicator that enables monitoring the dose, time and date of each injection and allows feedback control by doctors. The objective was to assess the cost-effectiveness of monitored rhGH treatment administered by Easypod with an increase in reimbursement of 10% compared to the standard non-monitored rhGH administration in CR. METHODS: The interim results (n=596) of an ongoing multicenter, non-comparative, observational, longitudinal study (ECOS) were used to populate deterministic cohort model. The model simulated long-term costs and benefits development of rhGH treatment. Evaluation was developed primarily on evidence-based connection (from ECOS) between the monitoring of treatment and patient adherence to the treatment. Increased adherence of monitored patients was transferred to the increased effectiveness of the treatment, based on published study. Model further transformed the long-term treatment benefits to the increased quality of life, using QALY as the target parameter using empirical transformation. Costs were expressed from the payer’s perspective. RESULTS: Due to an increased adherence in monitored patients, the hypothetical cohort of 10,000 boys generated 9,517 incremental QALY and CZK 1.6 billion incremental costs in a lifetime horizon. A hypothetical cohort of 10,000 girls generated 11,504 incremental QALY and CZK 1.35 billion incremental costs. The average cost per 1 QALY (ICER) is approximately CZK 157,000 for the patient with GHD. CONCLUSIONS: Monitoring of the treatment may lead to an increased adherence and more effective treatment at relatively low cost, hence being considered cost-effective. Sensitivity analysis showed that ICER did not exceed CZK 500,000 upon the considered uncertainty.